Xeris Biopharma Holdings, Inc. (XERS)

Several events impacted Xeris Biopharma's stock price over the past six months. In August 2025, the company held its Second Quarter 2025 Financial Results Conference Call and Webcast. On November 5, 2025, Xeris showed earnings and held its Third Quarter 2025 Financial Results Conference Call and Webcast. In December 2025, Xeris Pharmaceuticals' stock rose after a rival drug from Corcept Therapeutics faced a setback with the FDA. In January 2026, Xeris Biopharma Holdings announced preliminary unaudited fourth quarter and full-year 2025 results, exceeding guidance, which led to a stock surge, but shares later declined due to profit-taking and insider selling. Short interest remained elevated.

The provided information does not explicitly detail any specific demand seasonality for Xeris Biopharma Holdings, Inc.'s products and services. However, the company has reported accelerating demand for Recorlev and continued strong Gvoke demand, suggesting consistent or growing demand rather than pronounced seasonal fluctuations.

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing ready-to-use therapeutic medicines. The company operates in the Healthcare sector and Pharmaceuticals industry, utilizing its XeriSol and XeriJect technologies to create liquid-stable injectable and infusible drugs. Key products include Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, Recorlev for Cushing's syndrome, and Ogluo for severe hypoglycemia. The company's pipeline includes XP-8121, a Phase 3 clinical trial drug for hypothyroidism.

Xeris Biopharma Holdings, Inc. is headquartered in Chicago, Illinois, where it was established in 2005. Keveyis is approved in the United States. The company is seeking international intellectual property protections for XP-8121, indicating potential future expansion.

Xeris Biopharma Holdings has a positive brand reputation due to strong financial performance and product demand. The company reported a revenue growth rate of 47.90% in July 2025, and its stock performance has exceeded industry and market benchmarks. Analysts generally hold a "Strong Buy" consensus rating. Positive adjusted EBITDA in every quarter of 2025 and a strengthened intellectual property portfolio also contribute to a favorable reputation. Insider selling has occurred, but the overall sentiment is positive due to the company's growth and pipeline.

Xeris Biopharma Holdings, Inc. has an ownership structure that includes both institutional and individual investors. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., D. E. Shaw & Co., Inc., Geode Capital Management, Llc, State Street Corp, Morgan Stanley and Nuveen, LLC. Vanguard Group Inc. held 6.742% ownership as of January 29, 2026. Institutional investors collectively hold 59.51% of shares outstanding, while individuals/insiders hold 5.18%.